Loading
PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signalling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation.
No product in this corpus aims at PIM2 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PIM2: RNA tissue enhanced (bone marrow 97 nTPM, intestine 82 nTPM, lymphoid tissue 153 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PIM2 tissue; Open Targets ENSG00000102096 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Baytel et al, Biochim. Biophys. Acta, 1998, "The human Pim-2 proto-oncogene and its testicular expression". Source.
Sources: HGNC HGNC:8987 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9P1W9 (protein name, function text, keywords and locations (REST API)); CIViC gene PIM2 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0))
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signalling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilisation of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signalling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Locus Xp11.23 (HGNC).
RNA: tissue enhanced (bone marrow 97 nTPM, intestine 82 nTPM, lymphoid tissue 153 nTPM), detected in all normal tissues.
No normal tissue stained high.
RNA cancer enriched: Testicular Germ Cell Tumor 385 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PIM2" OR ABSTRACT:"PIM2" OR TITLE:"Pim-2 proto-oncogene, serine/threonine kinase" OR ABSTRACT:"Pim-2 proto-oncogene, serine/threonine kinase" OR TITLE:"Serine/threonine-protein kinase pim-2" OR ABSTRACT:"Serine/threonine-protein kinase pim-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PIM2, not a curated reading list.